+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Nasopharyngitis (Common Cold) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830066
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 49 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Exscientia Ltd
  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Tris Pharma Inc
  • MORE
High levels of pipeline activity are being observed in Nasopharyngitis (Common Cold) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Charleston Laboratories Inc, Exscientia Ltd, Firebrick Pharma Pty Ltd , Karo Pharma AB, Orbis Biosciences Inc and others.

A Significant contribution to the Nasopharyngitis (Common Cold) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Nasopharyngitis (Common Cold) pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Nasopharyngitis (Common Cold) condition and increased access to investments is encouraging growth of Nasopharyngitis (Common Cold) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Nasopharyngitis (Common Cold) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Nasopharyngitis (Common Cold) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Nasopharyngitis (Common Cold) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Nasopharyngitis (Common Cold). Further, orphan drug status, fast track designation, grants awarded and other special status for Nasopharyngitis (Common Cold) pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Nasopharyngitis (Common Cold) pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Nasopharyngitis (Common Cold) Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Nasopharyngitis (Common Cold) drugs
  • Late phase: Phase 3 and in-approval Nasopharyngitis (Common Cold) drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Nasopharyngitis (Common Cold) therapeutic treatment activities
Details for each Nasopharyngitis (Common Cold) drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Nasopharyngitis (Common Cold) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Exscientia Ltd
  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Tris Pharma Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Nasopharyngitis (Common Cold)- Disease Overview
2.2 Nasopharyngitis (Common Cold)- Pipeline Snapshot
2.3 Nasopharyngitis (Common Cold)- Pipeline Drugs by Phase
2.4 Nasopharyngitis (Common Cold)- Pipeline Drugs by Company
2.5 Nasopharyngitis (Common Cold)- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Charleston Laboratories Inc Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.2 Exscientia Ltd Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.3 Firebrick Pharma Pty Ltd Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.4 Karo Pharma AB Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.5 Orbis Biosciences Inc Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.6 Sanotize Research And Development Corp Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019
3.7 Tris Pharma Inc Nasopharyngitis (Common Cold) Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Nasopharyngitis (Common Cold)- Phase 1 Drug Details
4.2 Nasopharyngitis (Common Cold)- Phase 1 Drug Overview
4.3 Nasopharyngitis (Common Cold)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Nasopharyngitis (Common Cold)- Phase 2 Drug Details
5.2 Nasopharyngitis (Common Cold)- Phase 2 Drug Overview
5.3 Nasopharyngitis (Common Cold)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Nasopharyngitis (Common Cold)- Phase 3 Drug Details
6.2 Nasopharyngitis (Common Cold)- Phase 3 Drug Overview
6.3 Nasopharyngitis (Common Cold)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Nasopharyngitis (Common Cold)- Pre-clinical Phase Drug Details
7.2 Nasopharyngitis (Common Cold)- Pre-clinical Phase Drug Overview
7.3 Nasopharyngitis (Common Cold)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Charleston Laboratories Inc
  • Exscientia Ltd
  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Sanotize Research And Development Corp
  • Tris Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll